Kurma Partners

Coave Therapeutics specializes in developing gene therapies aimed at treating rare ocular and central nervous system diseases. The company focuses on innovative solutions for rare retinal disorders, utilizing a recombinant adeno-associated virus that substitutes the viral DNA with a functional copy of the PDE6B gene. This therapeutic approach involves injecting the corrected version of the protein between the photoreceptors and the retinal pigment epithelium, providing patients with effective treatment options for various eye conditions.

Vico Therapeutics B.V., founded in 2019 and based in Leiden, the Netherlands, specializes in developing RNA modulating therapies aimed at treating rare neurological disorders. The company's primary focus is on conditions such as spinocerebellar ataxias, Huntington’s disease, and Rett syndrome. By discovering and delivering innovative therapies, Vico Therapeutics aims to address the unmet medical needs of patients suffering from these severe central nervous system disorders, thereby enhancing treatment options available to medical professionals.

Stilla Technologies is a biotechnology company based in Villejuif, France, with an additional location in Beverly, Massachusetts. Founded in 2013, the company specializes in accelerating the development of next-generation genetic tests through its innovative digital PCR (dPCR) solution, the Naica System. This platform leverages advanced microfluidic technology to provide a flexible and accessible tool for high-resolution genetic analysis. By enabling compatibility with multiple chemistries and offering multiplex capabilities, Stilla Technologies aims to simplify the processes of image analysis and data exploration for researchers in various fields, including life sciences and therapeutics. The company's mission is to make digital PCR a standard tool across all areas of genetic research and application.

Vico Therapeutics B.V., founded in 2019 and based in Leiden, the Netherlands, specializes in developing RNA modulating therapies aimed at treating rare neurological disorders. The company's primary focus is on conditions such as spinocerebellar ataxias, Huntington’s disease, and Rett syndrome. By discovering and delivering innovative therapies, Vico Therapeutics aims to address the unmet medical needs of patients suffering from these severe central nervous system disorders, thereby enhancing treatment options available to medical professionals.

Stilla Technologies is a biotechnology company based in Villejuif, France, with an additional location in Beverly, Massachusetts. Founded in 2013, the company specializes in accelerating the development of next-generation genetic tests through its innovative digital PCR (dPCR) solution, the Naica System. This platform leverages advanced microfluidic technology to provide a flexible and accessible tool for high-resolution genetic analysis. By enabling compatibility with multiple chemistries and offering multiplex capabilities, Stilla Technologies aims to simplify the processes of image analysis and data exploration for researchers in various fields, including life sciences and therapeutics. The company's mission is to make digital PCR a standard tool across all areas of genetic research and application.

PathoQuest SAS is a biotechnology company that specializes in advanced metagenomics for pathogen detection, having originated as a spin-off from Institut Pasteur. The company utilizes proprietary next-generation sequencing (NGS) technology, which combines innovative sample preparation with a comprehensive database of pathogen genomic information. This approach allows clinicians and biopharmaceutical professionals to enhance the detection of infectious agents in various biological samples. PathoQuest's Viral Safety testing service, aimed at biopharmaceutical companies, represents its first commercial application and has rapidly generated revenue from major industry players. The company's cloud-based bioinformatics platform and automated analysis pipeline further facilitate improved pathogen detection, making its solutions valuable for both clinical and biopharmaceutical quality assurance.

DNA Script SAS, established in 2014 and headquartered in Paris, France, specializes in synthetic biology tools. The company's core product, SYNTAX, is a revolutionary benchtop DNA printer that uses enzymatic technology to rapidly produce synthetic oligonucleotides, genes, pathways, and genomes. This innovative approach empowers life science researchers and labs to print their own synthetic DNA, enhancing workflow control and accelerating access to results, thereby advancing breakthroughs in life science and human health.

Coave Therapeutics specializes in developing gene therapies aimed at treating rare ocular and central nervous system diseases. The company focuses on innovative solutions for rare retinal disorders, utilizing a recombinant adeno-associated virus that substitutes the viral DNA with a functional copy of the PDE6B gene. This therapeutic approach involves injecting the corrected version of the protein between the photoreceptors and the retinal pigment epithelium, providing patients with effective treatment options for various eye conditions.

Vico Therapeutics B.V., founded in 2019 and based in Leiden, the Netherlands, specializes in developing RNA modulating therapies aimed at treating rare neurological disorders. The company's primary focus is on conditions such as spinocerebellar ataxias, Huntington’s disease, and Rett syndrome. By discovering and delivering innovative therapies, Vico Therapeutics aims to address the unmet medical needs of patients suffering from these severe central nervous system disorders, thereby enhancing treatment options available to medical professionals.

Stilla Technologies is a biotechnology company based in Villejuif, France, with an additional location in Beverly, Massachusetts. Founded in 2013, the company specializes in accelerating the development of next-generation genetic tests through its innovative digital PCR (dPCR) solution, the Naica System. This platform leverages advanced microfluidic technology to provide a flexible and accessible tool for high-resolution genetic analysis. By enabling compatibility with multiple chemistries and offering multiplex capabilities, Stilla Technologies aims to simplify the processes of image analysis and data exploration for researchers in various fields, including life sciences and therapeutics. The company's mission is to make digital PCR a standard tool across all areas of genetic research and application.

PathoQuest SAS is a biotechnology company that specializes in advanced metagenomics for pathogen detection, having originated as a spin-off from Institut Pasteur. The company utilizes proprietary next-generation sequencing (NGS) technology, which combines innovative sample preparation with a comprehensive database of pathogen genomic information. This approach allows clinicians and biopharmaceutical professionals to enhance the detection of infectious agents in various biological samples. PathoQuest's Viral Safety testing service, aimed at biopharmaceutical companies, represents its first commercial application and has rapidly generated revenue from major industry players. The company's cloud-based bioinformatics platform and automated analysis pipeline further facilitate improved pathogen detection, making its solutions valuable for both clinical and biopharmaceutical quality assurance.

DNA Script SAS, established in 2014 and headquartered in Paris, France, specializes in synthetic biology tools. The company's core product, SYNTAX, is a revolutionary benchtop DNA printer that uses enzymatic technology to rapidly produce synthetic oligonucleotides, genes, pathways, and genomes. This innovative approach empowers life science researchers and labs to print their own synthetic DNA, enhancing workflow control and accelerating access to results, thereby advancing breakthroughs in life science and human health.

Stilla Technologies is a biotechnology company based in Villejuif, France, with an additional location in Beverly, Massachusetts. Founded in 2013, the company specializes in accelerating the development of next-generation genetic tests through its innovative digital PCR (dPCR) solution, the Naica System. This platform leverages advanced microfluidic technology to provide a flexible and accessible tool for high-resolution genetic analysis. By enabling compatibility with multiple chemistries and offering multiplex capabilities, Stilla Technologies aims to simplify the processes of image analysis and data exploration for researchers in various fields, including life sciences and therapeutics. The company's mission is to make digital PCR a standard tool across all areas of genetic research and application.

Minoryx Therapeutics is a biotechnology company based in Mataro, Spain, founded in 2011. The company specializes in discovering and developing innovative treatments for life-threatening rare diseases, with a particular focus on pediatric neurometabolic conditions of genetic origin. Minoryx is known for its development of pharmacological chaperones, a new generation of small molecule drugs designed to restore protein functionality, thereby addressing unmet medical needs in genetic diseases that severely affect the central nervous system. Additionally, Minoryx engages in repositioning-based projects to explore alternative therapeutic options for these challenging conditions.

PathoQuest SAS is a biotechnology company that specializes in advanced metagenomics for pathogen detection, having originated as a spin-off from Institut Pasteur. The company utilizes proprietary next-generation sequencing (NGS) technology, which combines innovative sample preparation with a comprehensive database of pathogen genomic information. This approach allows clinicians and biopharmaceutical professionals to enhance the detection of infectious agents in various biological samples. PathoQuest's Viral Safety testing service, aimed at biopharmaceutical companies, represents its first commercial application and has rapidly generated revenue from major industry players. The company's cloud-based bioinformatics platform and automated analysis pipeline further facilitate improved pathogen detection, making its solutions valuable for both clinical and biopharmaceutical quality assurance.

Coave Therapeutics specializes in developing gene therapies aimed at treating rare ocular and central nervous system diseases. The company focuses on innovative solutions for rare retinal disorders, utilizing a recombinant adeno-associated virus that substitutes the viral DNA with a functional copy of the PDE6B gene. This therapeutic approach involves injecting the corrected version of the protein between the photoreceptors and the retinal pigment epithelium, providing patients with effective treatment options for various eye conditions.

DNA Script SAS, established in 2014 and headquartered in Paris, France, specializes in synthetic biology tools. The company's core product, SYNTAX, is a revolutionary benchtop DNA printer that uses enzymatic technology to rapidly produce synthetic oligonucleotides, genes, pathways, and genomes. This innovative approach empowers life science researchers and labs to print their own synthetic DNA, enhancing workflow control and accelerating access to results, thereby advancing breakthroughs in life science and human health.

Vivet Therapeutics SAS is a biotechnology company focused on researching, developing, and commercializing gene therapy treatments for inherited liver disorders and orphan diseases. Founded in 2016 and based in Paris, France, the company employs a liver-targeting adeno-associated virus (AAV) vector to deliver therapeutic genes directly into hepatocytes, addressing genetic disorders at their source. Vivet is particularly known for its work on diseases such as Wilson disease, Progressive Familial Intrahepatic Cholestasis, and Citrullinemia Type I. In collaboration with the Fundacion para la Investigacion Medica Aplicada and the Centro de Investigación Medica Aplicada at the University of Navarra, Vivet aims to enhance gene delivery technologies and ensure long-term expression of therapeutic genes, thereby advancing the field of gene therapy for liver-related conditions.

DNA Script SAS, established in 2014 and headquartered in Paris, France, specializes in synthetic biology tools. The company's core product, SYNTAX, is a revolutionary benchtop DNA printer that uses enzymatic technology to rapidly produce synthetic oligonucleotides, genes, pathways, and genomes. This innovative approach empowers life science researchers and labs to print their own synthetic DNA, enhancing workflow control and accelerating access to results, thereby advancing breakthroughs in life science and human health.

Minoryx Therapeutics is a biotechnology company based in Mataro, Spain, founded in 2011. The company specializes in discovering and developing innovative treatments for life-threatening rare diseases, with a particular focus on pediatric neurometabolic conditions of genetic origin. Minoryx is known for its development of pharmacological chaperones, a new generation of small molecule drugs designed to restore protein functionality, thereby addressing unmet medical needs in genetic diseases that severely affect the central nervous system. Additionally, Minoryx engages in repositioning-based projects to explore alternative therapeutic options for these challenging conditions.

Asceneuron SA is a biotechnology company based in Lausanne, Switzerland, founded in 2012, that focuses on discovering and developing therapeutics for neurodegenerative disorders with significant unmet medical needs. The company targets conditions such as progressive supranuclear palsy, orphan tauopathies, Alzheimer’s disease, and Parkinson’s disease. Asceneuron aims to develop orally bioavailable small molecule drugs that address both symptomatic relief and disease progression for these debilitating conditions. Tauopathies, characterized by the accumulation of tau protein deposits in the brain, are a key area of focus, as they currently lack effective treatments. With the increasing prevalence of Alzheimer's disease posing a major healthcare challenge, Asceneuron aspires to become a leading entity in the biotech sector by providing innovative and more effective therapeutic options for patients suffering from neurodegenerative diseases. The company operates as a subsidiary of Merck KGaA.

PathoQuest SAS is a biotechnology company that specializes in advanced metagenomics for pathogen detection, having originated as a spin-off from Institut Pasteur. The company utilizes proprietary next-generation sequencing (NGS) technology, which combines innovative sample preparation with a comprehensive database of pathogen genomic information. This approach allows clinicians and biopharmaceutical professionals to enhance the detection of infectious agents in various biological samples. PathoQuest's Viral Safety testing service, aimed at biopharmaceutical companies, represents its first commercial application and has rapidly generated revenue from major industry players. The company's cloud-based bioinformatics platform and automated analysis pipeline further facilitate improved pathogen detection, making its solutions valuable for both clinical and biopharmaceutical quality assurance.

PathoQuest SAS is a biotechnology company that specializes in advanced metagenomics for pathogen detection, having originated as a spin-off from Institut Pasteur. The company utilizes proprietary next-generation sequencing (NGS) technology, which combines innovative sample preparation with a comprehensive database of pathogen genomic information. This approach allows clinicians and biopharmaceutical professionals to enhance the detection of infectious agents in various biological samples. PathoQuest's Viral Safety testing service, aimed at biopharmaceutical companies, represents its first commercial application and has rapidly generated revenue from major industry players. The company's cloud-based bioinformatics platform and automated analysis pipeline further facilitate improved pathogen detection, making its solutions valuable for both clinical and biopharmaceutical quality assurance.

PathoQuest SAS is a biotechnology company that specializes in advanced metagenomics for pathogen detection, having originated as a spin-off from Institut Pasteur. The company utilizes proprietary next-generation sequencing (NGS) technology, which combines innovative sample preparation with a comprehensive database of pathogen genomic information. This approach allows clinicians and biopharmaceutical professionals to enhance the detection of infectious agents in various biological samples. PathoQuest's Viral Safety testing service, aimed at biopharmaceutical companies, represents its first commercial application and has rapidly generated revenue from major industry players. The company's cloud-based bioinformatics platform and automated analysis pipeline further facilitate improved pathogen detection, making its solutions valuable for both clinical and biopharmaceutical quality assurance.

Meiogenix is a biotechnology company focused on developing innovative breeding technologies aimed at unlocking the untapped genetic diversity of various organisms. By modulating the frequency of homologous recombination in eukaryotic cells, the company enhances natural biodiversity. This approach enables the creation of new products that can help tackle pressing global food and industrial challenges. Through its advancements, Meiogenix contributes to the exploration and application of genetic resources, ultimately aiming to improve agricultural and industrial outputs.